Mechanism of Thrombosis During COVID-19 Infection Due to SARS-CoV-2 Virus and its Variants, and a Clinically Proven Strategy to Combat with Probiotics and their Immunomodulins
Authors: Reddy Malireddy 
Published: October 2022

The US patent 11,077,052 B1, issued in August of the year 2021, has been granted relying on the research conducted until September 2020, using the multiple mixed strain probiotics and their immunomodulins to prevent or treat COVID-19 due to SARS-CoV-2 and its limited variants. Since then the SARS-CoV- 2 virus continuously generated multiple variants with different genomic configurations, almost to the point of overriding the vaccines and medications. The objective of this research article is to evaluate the effectiveness of the invention outlined in the U.S. patent 11,077,052 B1 on the variants of SARS- CoV-2 evolved in the later years of 2020, 2021 and 2022. This research has great significance because vaccines are not totally effective because of the high rate of mutations of SARS-CoV-2 virus resulting in antigenically different variants, which are overriding the immunity conferred by vaccines. Thus, there is a definite need for a reliable alternative or adjuvant therapy, which can be used either by itself or used as adjuvant therapy along with vaccines to combat COVID-19 infection due to SAR-CoV-2 virus and its continuously mutating variants of different antigenicity. The results of this investigation proved that the use of multiple mixed strain probiotics along with their immunomodulins are effective not only on novel SARS-CoV-2 coronavirus evolved in late 2019 and mid 2020 but also the mutated variants in the later part of the years 2020, 2021, and 2022. The COVID-19 pandemic is not yet contained as of August 2022. The SARS-CoV- 2 virus has been continuously mutating generating variants which are resisting vaccines and the treatments. The death’s due to SARS -COV- 2 viral infections are attributed predominantly to cytokine storm and thrombosis resulting in ARDS (Acute Respiratory Disease Syndrome} and multi organ failure. The earlier published article thoroughly discussed about the genesis and control of cytokine storm to protect the victims. This article mainly emphasizes the Pathophysiology of thrombosis, due to SARS-CoV-2 virus and its recent multiple variants, and the ways and means of controlling it to prevent or cure COVID-19, using the multiple mixed strain probiotics and their Immunomodulins. The hormonal and enzymatic system variations causing the disturbance in homeostasis of the vascular system resulting in thrombosis, due to SARS-CoV-2 virus and its continuously evolving variants is thoroughly discussed. In addition, the infection pattern and progression of the SARS-CoV-2 virus causing endothelial cell lysis of the vascular system resulting in thrombosis has been elucidated with molecular details. The specific role of immunomodulins of the multiple mixed strain probiotics to prevent or treat COVID-19 disease induced thrombosis has also been presented. The physiological functions of individual components of the probiotics and the immunomodulins produced by the multiple mixed strain probiotics, is presented for the first time with explicitly proven molecular details, showing how they contribute individually and cumulatively to prevent or treat COVID-19 infection, due to SARS-CoV-2 virus and its multiple variants, generated during the years 2020 through 2022, to induce thrombosis.